紫杉醇、姜黄素为临床可行的抗乳腺癌活性成分。二者合用能够促乳腺癌细胞凋亡、抗肿瘤血管生成、降低紫杉醇的细胞毒性，且效果优于二者单用。本课题首次选择共同作用于乳腺癌但作用机制不同的紫杉醇和姜黄素，将二者包载于介孔SiO2 /脂质复合“隐形”递药系统（PLMSNs）中，发挥中药多组分整合、多靶点协同作用；采用PLMSNs提高载药量，克服紫杉醇和姜黄素共有的低生物利用度问题；利用PLMSNs的“隐形”长循环作用和在肿瘤部位的渗透滞留增强效应，使紫杉醇和姜黄素同时靶向作用于肿瘤部位，提高疗效，并从细胞分子生物学角度深入探讨PLMSNs中二者协同作用于犬乳腺癌细胞的分子调控机制。通过本课题的研究，将中医药理论与新型给药系统相结合，使中药活性成分在同一病灶发挥活血化瘀、抗癌解毒的协同治疗作用，以期获得药物载体的高容量携带、长循环靶向治疗等特性。

Taxol and curcumin deriving from clinical are two active ingredients against breast cancer. Combination use of them can induce apoptosis of breast cells, inhibit tumor angiogenesis and reduce cytotoxicity of paclitaxel. Meanwhile, combination therapy effect of taxol and.curcumin is better than single use of each one. This study will co-entrap taxol and curcumin which treat against breast cancer through different mechanisms into SiO2 / lipid complex "stealth" drug delivery system (PLMSNs) to realize multi-component and multi-target synergy of traditional Chinese medicine. PLMSNs will be used to increase drug loading and to improve the bioavailability of both paclitaxel and curcumin. Long circle effect and EPR effect (enhanced permeability and retention tumor position) of PLMSNs will promote the co-delivery of taxol and curcumin to the tumor lesion. Meanwhile, molecular mechanisms of how taxol and curcumin entrapped in PLMSNs act on canine breast cancer cells cooperatively will get further discussed based on molecular cell biology. Objective of this study is to combine TCM theory with new type of drug delivery system. At the same time, Taxol and curcumin’s synergistic therapeutic effects including blood-activating, stasis-dissolving, detoxification and anticancer on the same lesion are expected to be achieved. Furthermore, drug carrier’s characteristics of high drug loading and long circle targeting therapy will be acquired. This study is also expected to provide research foundation to the construction and evaluation of low-cost, high-performance mesoporous SiO2 / lipid "stealth" complex drug delivery systems of traditional Chinese medicine.